We retrospectively evaluated short-and long-term effects of percutaneous transluminal renal angioplasty (PTRA) with or without stent placement of renal artery occlusion (RAO) upon blood pressure (BP), serum (s)-creatinine, and the need for antihypertensive treatment in 34 RAO patients who underwent PTRA during 1996-2002. In 24/34 (71%) treatment was considered technically successful, 22/24 (92%) were treated with PTRA þ stent, two with only PTRA. Patients were followed for mean 2.6 (range 0-8) years, during which 14/34 (41%) patients died. In all 34 patients, systolic and diastolic BP (SBP and DBP) before treatment were 184730/95715 mmHg and had decreased at discharge (to 157721/80710 mmHg; Po0.001 for both SBP and DBP), and remained lower after 1 year (154720/ 8377 mmHg;Po0.001 for SBP and Po0.01 for DBP), and at last follow-up (148720/80712 mmHg; Po0.001 for both SBP and DBP). No changes occurred in s-creatinine or the number of antihypertensive drugs. Similar results were seen in the subgroup of 24/34 (71%) patients in whom treatment was technically successful. Among the 24 patients undergoing technically successful PTRA, absence of nephrosclerosis (P ¼ 0.035) and a shorter duration of hypertension (P ¼ 0.020) predicted favourable clinical outcome. No adverse effects upon s-creatinine or the need for antihypertensive medication were seen in patients in whom treatment was considered a technical failure. Seven of these patients were treated with PTRA of another renal artery than the occluded, or with embolisation. In conclusion, RAO can be treated with endovascular techniques. Technically successful results with decreasing blood pressure levels were obtained in 71% of patients.
Introduction
Renal artery occlusion (RAO) can occur chronically due to atherosclerosis, acutely due to trauma, or as a complication during surgical or endovascular procedures. 1 RAO can occur unnoticed and may, like renal artery stenosis (RAS), present itself clinically as a cause of arterial hypertension. 1 Historically, surgical revascularisation has been the standard therapy for RAO 2, 3 or RAS in a solitary kidney. 4 Currently established treatments of RAO are either open surgery or conservative follow-up with medical antihypertensive therapy, whereas percutaneous transluminal renal angioplasty (PTRA) is an established treatment of RAS. At our institution, we have also treated RAO patients with endovascular methods since the middle of the 1990s. The aim of this study was to evaluate retrospectively short-and longterm effects of PTRA with or without stenting in RAO upon blood pressure (BP), serum (s-) creatinine levels, and the need for antihypertensive treatment.
Material and methods

Material
During 1996-2002, 38 patients with RAO underwent a percutaneous revascularisation attempt at Malmö University Hospital, out of which 34 (mean age 65 years, range 7-78 years, 14 women) had noniatrogenous RAO. Of these 34 patients, 33 had atherosclerotic RAO and a 7-year-old-girl had RAO due to neurofibromatosis. Four patients had iatrogenous RAO that occurred during surgical or endovascular treatment for aortic dissection (n ¼ 1) or abdominal aortic aneurysm (n ¼ 3). These four patients were excluded from this report as well as the 22 RAO patients diagnosed during 1996-2002 in whom no PTRA was attempted because of renal size o7 cm and unvisualised refilling of the renal arteries in both the early and late phases of renal angiography.
This report is thus focused upon all 34 patients who underwent PTRA because of noniatrogenous RAO. RAO was defined as complete renal artery occlusion with no anterograde perfusion of the renal artery. All 34 patients had undergone renal angiography because of renovascular arterial hypertension. Four patients with RAO included in this study had undergone successful surgical or endovascular treatment 2 weeks-7 years previously on kidneys with RAS, which had now occluded. Patient characteristics are given in Table 1 . In all, 27 patients (79%) were over 60 years of age and 15 patients (44%) were over 70 years of age. Screatinine was 4500 mmol/l in four patients and 250-500 mmol/l in nine patients. Two patients required haemodialysis already before PTRA, another three patients required dialysis during followup. (All these patients had undergone PTRA despite an already impaired renal function (s-creatinine 373-1002 mmol/l) in order to delay terminal renal failure or need for dialysis.) Pulmonary oedema had previously occurred in four patients, accelerated heart failure in two patients, and other signs of heart failure in five patients. The length of the RAO was 1.971.2 cm.
Methods
Patient files at Malmö University Hospital and other referring hospitals in the region were checked for follow-up data concerning blood pressure (BP), screatinine, and the need for antihypertensive treatment, body mass index (BMI), smoking habits, the presence or absence of diabetes mellitus and the known duration of hypertension. Blood pressures had been measured in the right arm in the supine position after 5 min rest. If several measurements were performed at the same occasion, the median of the measurements were used.
Reference values for s-creatinine were 51-105 mmol/l. Patients with s-creatinine X130 mmol/l underwent CO 2 -angiography. In two cases complementary local fibrinolysis with 3-4 mg alteplase (Actilyse s ) was necessary. Due to their effects upon BP, diuretics and nitrates were defined as antihypertensive drugs, even though they may have primarily been given for other reasons.
At follow-up, the diagnosis of RAO was confirmed in each case by reviewing renal angiography, the gold standard for renal artery imaging. From the renal angiographic findings, renal size (pole to pole measure), the characters and length of the renal artery occlusion and the presence or absence of nephrosclerosis were determined in all patients. During this process, two independent reviewers (BL þ AA) reviewed the angiographies blinded with respect to clinical outcome. Control renal angiography was performed if reocclusion or stenosis was suggested by the recurrence of uncontrollable hypertension or by deterioration of renal function.
Information about the causes of death was obtained through the death registry of the Swedish Board of Health and Welfare.
Definitions of effects and results
Technical success and failure
Technical success was defined as successful dilatation of the occluded artery, with residual stenosis o30%, and residual medial pressure gradient o10 mmHg at the end of the PTRA procedure. Technical failure was defined as either failure to dilate the occluded artery, or a major complication such as dissection, perforation or immediate reocclusion during the PTRA procedure.
Effects on BP
Success-Diastolic BP after treatment was o95 mmHg without medication or lowered X20 mmHg without increased medication.
Improvement-Diastolic BP was o95 mmHg or did not increase more than 6% in spite of reduced (12) 2 (20) medication or the diastolic BP was lowered X10% or the systolic BP was lowered X20% without increased medication. Deterioration-The number of antihypertensive drugs was increased without lowering of the diastolic BP or the diastolic BP increased 46% without reduction of medication.
Effects on renal function
Since this was a retrospective study and we did not have access to clearance data, effects on renal function were based on s-creatinine values.
Improved-s-creatinine. was reduced X20%. Unchanged-s-creatinine changed o20%. Deteriorated-s-creatinine increased p20.
Overall treatment results
Success-BP effect was success or improvement and s-creatinine was normal or improved.
Unchanged Stable-The result of one parameter was success or improvement but the other had deteriorated.
Deterioration-One parameter deteriorated without improvement of the other.
Statistics
Differences between groups were evaluated with the Mann-Whitney U test, and differences over time within a group with the Wilcoxon Signed Rank test. Differences in frequency were evaluated with the w 2 -test. Tests were two-tailed and P-values o0.05 were considered significant. Results are presented as mean7s.d. StatView 4.5 (SAS Institute, Cary, NC, USA) was used for the statistical calculations.
Results
All patients
Patients were followed for mean 2.6 (range 0-8) years, during which 14 (41%) patients died. In all 34 patients, systolic and diastolic blood pressures (SBP and DBP) before treatment were 184730/ 95715 mmHg and had decreased at discharge (to 157721/80710 mmHg; Po0.001 for both SBP and DBP), and remained lower after 1 year (154720/ 8377 mmHg; Po0.001 for SBP and o0.01 for DBP), and at last follow-up (148720/80712 mmHg; Po0.001 for both SBP and DBP) ( Table 2) . No significant changes occurred in s-creatinine or the number of antihypertensive drugs.
Patients in whom treatment was technically successful
In 24/34 (71%) patients treatment was considered as technically successful (Figure 1 ), 22/24 (91%) were treated with PTRA þ stent (Palmaz s or Jomed s ), two with only PTRA. The above significant effects on BP were seen in the 24/34 (71%) patients in whom treatment was technically successful (Table 2) . In this group, s-creatinine improved or was unchanged in 21/24 patients (87.5%), and the antihypertensive medication was reduced in 8/24 (33%) patients (Figure 2 ). Six (25%) of the patients had solitary functioning kidneys. 
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Among the 24 patients undergoing technically successful PTRA of chronic atherosclerotic RAO, statistical comparisons between patients classified as having benefit vs nonbenefit ( ¼ unchanged or deterioration) revealed that the prevalence of nephrosclerosis was lower (P ¼ 0.035) and the duration of hypertension was shorter (P ¼ 0.020) in patients deriving benefit from PTRA, whereas there were no significant differences in renal size or oclusion length between patients classified as having benefit or nonbenefit (Figure 1) . Control angiography was performed in 14/24 (58%) patients. In 10 cases perfusion was patent, whereas reocclusion was found in three and restenosis in one patient. In this patient a new PTRA and stenting was performed.
Patients in whom treatment was considered a technical failure
In the 10/34 (29%) of patients in whom revascularisation failed, no significant changes in BP, s-creatinine, or number of antihypertensive drugs were seen until last follow-up, when both SBP and DBP had decreased compared to before treatment (Po0.05) ( Table 2 ). In this group, however, four patients underwent PTRA on RAS in the ipsi-or contralateral kidneys, and three patients were treated by embolisation because of perforation of the main renal artery during PTRA attempt of the RAO. One patient was later operated because of failure to recanalise the RAO, and the remaining two patients got renal artery dissections.
Complications
The complications, mortality and causes of death are reported in detail in Table 3 . The total number of patients with X1 complication was 13/34 (38%). The stent misplacement resulted in stent migration causing intermittent claudication, necessitating later successful PTA treatment of the common iliac artery. All three cases of accelerated heart failure occured 430 days after the PTRA, with no apparent relation to the procedure. In one of the three cases the PTRA was considered a technical failure because of dissection of the renal artery. In all three cases s-creatinine was 4200 at the time of PTRA.
Discussion
In our retrospective study of patients with renal artery occlusion, PTRA was effective for the treatment of hypertension. PTRA could therefore well be attempted before considering surgical intervention on patients with solitary functioning kidneys.
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In patients with chronic renal insufficiency and global obstructive atherosclerotic vascular disease, PTRA and stenting of renal artery stenosis has been shown to improve or stabilise renal function and to preserve kidney size, 9 and Shannon et al 10 have advocated stenting as a relatively safe procedure to salvage a solitary kidney. Repeated PTRA and stent placement have previously been reported to be effective treatment for total RAO after prior unsuccessful balloon angioplasty. 11, 12 We now extend those findings by showing persistent effects upon BP with PTRA and stenting of RAO. As this is a retrospective nonrandomised study, the possibility that our results might be partly explained by regression towards the mean cannot be excluded, however.
Renal artery stents became available in our department in 1995 and were used in the vast majority of patients in this study. In the two patients who were not stented in our study, the decision to refrain from stenting was made because the opened RAO was located in a renal branch artery.
Surprisingly, effects upon BP were seen at last follow-up even among RAO patients in whom PTRA had been technically unsuccessful. This might most probably have been due to the fact that PTRAs were performed on contralateral kidneys or on ipsilateral branch-or pole arteries, or to that renin production from some kidneys might have been completely ablated through embolisation or dissection 13 in seven of these 10 cases.
The presence of nephrosclerosis and a longer duration of hypertension were significant negative predictors of beneficial clinical outcome of PTRA in patients undergoing technically successful PTRA of RAO in our study. The presence of collateral circulation or refilling of the peripheral circulation is no guarantee for a successful outcome of PTRA. However, kidney function can be restored after prolonged main renal artery occlusion and renal failure when glomerulosclerosis is absent and when renal mass is normal. 14 The duration of hypertension has previously been demonstrated to be a predictor of a negative outcome of PTRA in RAS, 15, 16 and we now verify this finding also for patients with renal artery occlusion. Deterioration in renal function after PTRA has more often been described in patients older than 70 years. 10 It is therefore important to notice that our patients were older in comparison with reports from other centres, 27/34 (79%) were older than 60 years and 15/34 (44%) were older than 70 years, which might help to explain part of the complications in our material.
It has been suggested that no useful renal function can be retrieved by revascularisation in patients with renal size o8 cm. 17 Rubin and co-workers 7 on the other hand, proposed that nephrectomy is indicated in patients with severe hypertension and kidney size o7 cm with a shrunken cortex and surgically unreconstructable renovascular disease, of either the main renal artery or of the branch vessels. No PTRA attempts were therefore made in our institution on patients with kidney size o7 cm. Also among patients in our study with kidney size above this limit, however, the patients showing successful results of PTRA on total RAO tended to have larger kidney size than patients with nonbeneficial results, although this difference did not reach statistical significance, as shown in Figure 1 . We therefore agree that transcatheter renal ablation, [18] [19] [20] [21] if possible without interfering with spinal cord circulation, or nephrectomy should be performed in patients with severe or uncontrollable hypertension in whom the size of the affected kidney is o7 cm, if the contralateral kidney is healthy and has a normal function. When the main renal artery is occluded, endovascular renal ablation might be cumbersome, since the collateral flow to the kidney is hard to evaluate correctly. Owing to the high mortality and morbidity with surgical measures in patients with high s-creatinine levels, 17 nephrectomy should be reserved for patients in whom the above measures are impossible, however. Laparoscopic nephrectomy has also been used in our hospital as an alternative to open surgical nephrectomy.
On the other hand, we advocate conservative treatment in patients with mild hypertension that could be controlled with two antihypertensive drugs or less who have small nephrosclerotic kidneys, as the high BP may decrease or disappear spontaneously when the occluded kidney loses its biological function. 13 The presence of biological active renal tissue in an atrophied (o7 cm) kidney with RAO probably is a crucial factor in the pathogenesis of uncontrolled hypertension. 13 Lasry et al 22 reported that a short renal artery occlusion is a positive predictor of a favourable result of PTRA. However, we observed successful PTRA outcomes also in some patients with long renal artery occlusions. The renal artery diameter distal to the RAO should also be considered; a narrow irregular renal artery segment extending toward the periphery distal to the occlusion, a manifestation of nephrosclerosis, was associated with failure of the PTRA procedure and complications in many of our patients.
The refilling of the main renal artery, indeed reflecting the presence of collateral circulation, is a prerequisite for a successful outcome of PTRA. In our study, the renal artery refilling and its character were determined by renal angiography. However, with ongoing developments in the radiological field CT angiography and MR techniques may soon be superior to angiography.
In conclusion, PTRA was effective for the treatment of hypertension in patients with renal artery occlusion without adverse effects upon renal function. The presence of nephrosclerosis and longstanding hypertension negatively influenced the clinical results of a technically successful PTRA.
